ArticleNeuron2012
"Huntingtin holiday": progress toward an antisense therapy for Huntington's disease.
Article in Neuron, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 54 citations in OpenAlex.
- Epigenetic editing for autosomal dominant neurological disorders.Frontiers in genome editing · 2024Review
- Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model.JCI insight · 2022Article
- PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease.Molecular therapy. Methods & clinical development · 2022Article
- Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.Biomedicines · 2022Review
- Article
- Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.Molecular neurobiology · 2022Review
- Gene targeting techniques for Huntington's disease.Ageing research reviews · 2021Review
- Antisense Drugs Make Sense for Neurological Diseases.Annual review of pharmacology and toxicology · 2021Review
- Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.Nature reviews. Neurology · 2020Review
- Huntingtin Lowering Strategies.International journal of molecular sciences · 2020Review
- Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?Frontiers in cellular neuroscience · 2020Review
- A randomised feasibility study of computerised cognitive training as a therapeutic intervention for people with Huntington's disease (CogTrainHD).Pilot and feasibility studies · 2020Article
- Recent advances in molecular therapies for neurological disease: triplet repeat disorders.Human molecular genetics · 2019Review
- The effects of huntingtin-lowering: what do we know so far?Degenerative neurological and neuromuscular disease · 2019Review
- Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7.Science translational medicine · 2018Article
- Converging pathways in neurodegeneration, from genetics to mechanisms.Nature neuroscience · 2018Review
- Metformin reverses early cortical network dysfunction and behavior changes in Huntington's disease.eLife · 2018Article
- Therapy development in Huntington disease: From current strategies to emerging opportunities.American journal of medical genetics. Part A · 2018Review
- Gene suppression approaches to neurodegeneration.Alzheimer's research & therapy · 2017Review
- Therapies targeting DNA and RNA in Huntington's disease.The Lancet. Neurology · 2017Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lowering mutant Huntingtin is a consensus therapeutic strategy for Huntington's disease. In this issue of Neuron, Kordasiewicz et al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.